Mydriasis

Occasionally, treatments come along that are of greater interest to patients than to doctors.

Unexplained mydriasis with cycloplegia in children and teens can cause great parental concern, especially if the patient reports an inability to do schoolwork.

Ryzumvi effectively reduced pharmacologically induced mydriasis within 60 to 90 minutes compared with placebo, while also exhibiting a favorable safety profile, according to results from two studies published in Ophthalmology.

Viatris is launching the first commercially available, FDA-approved eyedrop for the reversal of dilation, according to a press release.

FRANKFURT, Germany — In children’s eyes with insufficient capsular support, intrascleral IOL fixation with the Yamane technique leads to good visual outcomes and few intraoperative and postoperative complications.

In this Healio Video Perspective, Cathleen M. McCabe, MD, discusses a presentation from the ESCRS meeting on phentolamine 0.75%.

The FDA approved Ryzumvi for the treatment of pharmacologically induced mydriasis produced by adrenergic agonists or parasympatholytic agents, according to a press release from Ocuphire Pharma and Viatris.

SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Jay S. Pepose, MD, PhD, presents two products currently in development by Ocuphire Pharma, one for the front and one for the back of the eye.

SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Norbert Lowe and Michael Rowe of Eyenovia announce the FDA approval of Mydcombi, an ophthalmic spray designed to induce mydriasis.

The FDA has approved Eyenovia’s Mydcombi ophthalmic spray for inducing mydriasis, the company announced in a press release.